Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Nivolumab + Ipilimumab in Advanced RCC (CheckMate 920)
NCT02982954Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of nivolumab and ipilimumab in renal cell carcinoma (RCC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With High Grade (Grade 3-4) Immune Mediated Adverse Events at 39 months and Number of Participants With High Grade (Grade 5) Immune Mediated Adverse Events at 39 months. Started Jan 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02982954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982954.